{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:45Z","timestamp":1793664825707,"version":"4.5.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08121-y","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:46:08Z","timestamp":1776707168000},"page":"3289-3294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Application of BCMA CAR-T in systemic lupus erythematosus"],"prefix":"10.1007","volume":"45","author":[{"given":"Hailing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanggang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5530-1992","authenticated-orcid":false,"given":"Bo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"3","key":"8121_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.berh.2017.09.013","volume":"31","author":"MY Choi","year":"2017","unstructured":"Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE (2017) A review on SLE and malignancy. Best Pract Res Clin Rheumatol 31(3):373\u2013396","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8121_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4939-8546-3_2","volume":"1802","author":"G Bodis","year":"2018","unstructured":"Bodis G, Toth V, Schwarting A (2018) Role of human leukocyte antigens (HLA) in autoimmune diseases. Methods Mol Biol 1802:11\u201329","journal-title":"Methods Mol Biol"},{"issue":"22","key":"8121_CR3","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110\u20132121","journal-title":"N Engl J Med"},{"issue":"10","key":"8121_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/0961203319860198","volume":"28","author":"M Frodlund","year":"2019","unstructured":"Frodlund M, Reid S, Wettero J, Dahlstrom O, Sjowall C, Leonard D (2019) The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. Lupus 28(10):1261\u20131272","journal-title":"Lupus"},{"issue":"2","key":"8121_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","volume":"17","author":"S Fillatreau","year":"2021","unstructured":"Fillatreau S, Manfroi B, Dorner T (2021) Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol 17(2):98\u2013108","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"8121_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","volume":"14","author":"V Peperzak","year":"2013","unstructured":"Peperzak V, Vikstr\u00f6m I, Walker J, Glaser SP, LePage M, Coquery CM et al (2013) Mcl-1 is essential for the survival of plasma cells. Nat Immunol 14(3):290\u20137","journal-title":"Nat Immunol"},{"issue":"4","key":"8121_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/08916934.2020.1736049","volume":"53","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yang M, Long D, Li Q, Zhao M, Wu H et al (2020) Abnormal expression of BAFF and its receptors in peripheral blood and skin lesions from systemic lupus erythematosus patients. Autoimmunity 53(4):192\u2013200","journal-title":"Autoimmunity"},{"issue":"9767","key":"8121_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721\u201331","journal-title":"Lancet"},{"issue":"12","key":"8121_CR9","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918\u20133930","journal-title":"Arthritis Rheum"},{"key":"8121_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","volume":"86","author":"L Iaccarino","year":"2018","unstructured":"Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F et al (2018) Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun 86:1\u20138","journal-title":"J Autoimmun"},{"issue":"9","key":"8121_CR11","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1093\/rheumatology\/keaa796","volume":"60","author":"I Parodis","year":"2021","unstructured":"Parodis I, Vital EM, Hassan SU, Jonsen A, Bengtsson AA, Eriksson P et al (2021) De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford) 60(9):4348\u20134354","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"8121_CR12","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/blood.2025028375","volume":"146","author":"F Muller","year":"2025","unstructured":"Muller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A et al (2025) Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood 146(9):1088\u201395","journal-title":"Blood"},{"issue":"9","key":"8121_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G, Muller F, Taubmann J, Mackensen A, Wang W, Furie RA et al (2024) Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol 20(9):531\u201344","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"8121_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-026-01779-6","volume":"19","author":"M Hong","year":"2026","unstructured":"Hong M, Wang M, Zeng R, Ding L, He S, Lan T et al (2026) BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial. J Hematol Oncol 19(1):13","journal-title":"J Hematol Oncol"},{"issue":"10","key":"8121_CR15","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M et al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83(10):1304\u201314","journal-title":"Ann Rheum Dis"},{"key":"8121_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1455464","volume":"14","author":"IS Hamadeh","year":"2024","unstructured":"Hamadeh IS, Friend R, Mailankody S, Atrash S (2024) Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed\/refractory multiple myeloma. Front Oncol 14:1455464","journal-title":"Front Oncol"},{"issue":"1","key":"8121_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12016-025-09114-6","volume":"68","author":"A Matarneh","year":"2025","unstructured":"Matarneh A, Matarneh B, Salameh O, Akkari A, Ghahramani N, Trivedi N (2025) Chimeric antigen receptor T cell therapy in systemic lupus erythematosus: mechanisms, clinical advances, and future directions a comprehensive review. Clin Rev Allergy Immunol 68(1):103","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08121-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08121-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08121-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:25:54Z","timestamp":1780982754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08121-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8121"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08121-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of second affiliated hospital of Xi\u2019an Jiaotong University. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants for the publication of anonymized aggregated data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}